Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (17 October 2017)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 95 US patents relevant to Australia's Life Sciences sector that have been granted since the start of 2017, for an issuance rate of 2.3 per week:

US Patent 9,790,176, Compounds for the treatment of mTOR pathway related diseases, Pharmaust (ASX: PAA), 17 October 2017
US Patent 9,789,177, Immunogenic protein Pas n 1 from Bahia grass pollen, University of Queensland and Queensland University of Technology, 17 October 2017
US Patent 9,789,168, Use of angiogenin or angiogenin agonists for treating diseases and disorders, Agriculture Victoria Services Pty Ltd and Murray Goulburn Co-Operative Co. Ltd, 17 October 2017
US Patent 9,783,599, LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same, Patrys (ASX: PAB), 10 October 2017
US Patent 9,770,503, Immunomodulating compositions and uses therefor, Walter and Eliza Hall Institute of Medical Research, 3 October 2017
US Patent 9,770,431, Tiglien-3-one derivatives, Neoculi, 3 October 2017
US Patent 9,765,129, Treatment of obesity, Omniblend Innovation (part owned by EVE Investments, ASX: EVE), 3 October 2017
US Patent 9,765,113, Methods and agents for the treatment of cancer, InterK Peptide Therapeutics, 19 September 2017
US Patent 9,764,002, Dosage regimen for therapeutic method, Madeleine Pharmaceuticals, 19 September 2017
US Patent 9,758,585, Compositions and methods for targeting type 1 interferon producing cells, Baker Medical Research Institute and Christian-Albrechts-Universitat zu Kiel (Germany), 19 September 2017
US Patent 9,757,391, Neuroactive steroids and their use to facilitate neuroprotection, Goodchild Investments Pty Ltd, 12 September 2017
US Patent 9,750,777, Methods and compositions for bone and cartilage repair, Cimtech Pty Ltd, 5 September 2017
US Patent 9,745,558, VEGFR-3 ligand binding molecules and uses thereof, Opthea (ASX: OPT), 29 August 2017
US Patent 9,744,246, Macromolecules, Starpharma (ASX: SPL), 29 August 2017
US Patent 9,738,591, Antimicrobial compounds, Ramiz Boulos, 22 August 2017
US Patent 9,737,559, Synergistic anti-diabetic compositions, Ozstar Therapeutics, 22 August 2017
US Patent 9,737,386, Dosage projectile for remotely treating an animal, SmartVet Pty Ltd, 22 August 2017
US Patent 9,732,329, Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof, University of Technology, Sydney, 15 August 2017
US Patent 9,732,136, VIP fragments and methods of use, Vectus Biosystems (ASX: VBS), 15 August 2017
US Patent 9,731,011, Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma, EnGeneIC, 15 August 2017
US Patent 9,731,007, Tumour necrosis factor receptor fusion proteins and methods of using the same, Nexvet, 15 August 2017
US Patent 9,730,964, Pharmaceutical compositions and topical use thereof, Regeneus (ASX: RGS), 15 August 2017
US Patent 9,730,897, Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells, EnGeneIC, 15 August 2017
US Patent 9,725,399, Lipid comprising long chain polyunsaturated fatty acids, Commonwealth Scientific and Industrial Research Organisation, Nuseed Pty Ltd, and Grains Research and Development Corporation, 8 August 2017
US Patent 9,724,329, Stimulating immune response, Peter MacCallum Cancer Institute, 8 August 2017
US Patent 9,718,887, Methods and products for preventing and/or treating metastatic cancer, University of Adelaide and Peter MacCallum Cancer Institute, 1 August 2017
US Patent 9,718,759, Lipid comprising docosapentaenoic acid, Commonwealth Scientific and Industrial Research Organisation and Grains Research and Development Corporation, 1 August 2017
US Patent 9,717,778, Combination therapy, Antisense Therapeutics (ASX: ANP), 1 August 2017
US Patent 9,717,771, Sugar extract, The Product Makers (Australia) Pty Ltd, 1 August 2017
US Patent 9,717,688, Controlled release of biological entities, Australian Nuclear Science & Technology Organisation, 1 August 2017
US Patent 9,713,642, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma (ASX: MYX), 25 July 2017
US Patent 9,713,632, Method of treatment, Hexima, 25 July 2017
US Patent 9,708,377, Scorpion toxin analogue and method for treating autoimmune diseases, Monash University, Peptides International (US) and Baylor College of Medicine (US), 18 July 2017
US Patent 9,707,205, S1P receptors modulators and their use thereof, Akaal Pharma, 18 July 2017
US Patent 9,701,711, Modulators of protease activated receptors, University of Queensland, 11 July 2017
US Patent 9,701,694, Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals, University of Melbourne, 11 July 2017
US Patent 9,695,160, Piperazine derivatives for treating disorders, University of Nottingham (UK) and University of New South Wales, 4 July 2017
US Patent 9,682,115, Herbal compositions for the prevention or treatment of benign prostatic hyperplasia and related disorders, Seipel Group, 20 June 2017
US Patent 9,676,819, Immunostimulatory method, Innavac Pty Ltd, 13 June 2017
US Patent 9,675,727, Method and device for treating bursitis, Mediwise, 13 June 2017
US Patent 9,675,694, Polycyclic agents for the treatment of respiratory syncytial virus infections, Biota, 13 June 2017
US Patent 9,675,553, Composition and method for management of diabetes or pre-diabetes, Omniblend Innovation (part owned by EVE Investments, ASX: EVE), 13 June 2017
US Patent 9,668,945, Fluoride composition and methods for dental mineralization, University of Melbourne, 6 June 2017
US Patent 9,663,786, Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 30 May 2017
US Patent 9,663,777, Component of bromelain, Anatara Lifesciences (ASX: ANR), 30 May 2017
US Patent 9,663,584, Antibodies to non-functional P2X7 receptor, Biosceptre, 30 May 2017
US Patent 9,662,368, Formulation comprising whey protein and hydrolysates for improving muscle recovery, Murray Goulburn Co-operative Co. Ltd, 30 May 2017
US Patent 9,655,946, Daptomycin formulations and uses thereof, Hospira Australia, 23 May 2017
US Patent 9,649,512, One or more of Vigna marina, Cocos nucifera L. or Terminalia catappa L. extracts for treating wounds, skin disorders and hair loss, Cimtech, 16 May 2017
US Patent 9,649,318, Formulation of meloxicam, iCeutica, 16 May 2017
US Patent 9,649,297, Treatment of ADHD, Gosforth Centre (Holdings) Pty Ltd, 16 May 2017
US Patent 9,649,275, Nanoemulsions, Commonwealth Scientific and Industrial Research Organisation, 16 May 2017
US Patent 9,642,897, Treatment of bone diseases, University of Sydney, 9 May 2017
US Patent 9,637,527, Method for treating inflammation with an Ac-TMP-2 protein, James Cook University, 2 May 2017
US Patent 9,636,334, Combination of lenalidomide and polypeptide construct, and uses thereof, Teva Pharmaceuticals Australia, 2 May 2017
US Patent 9,624,294, Antibody recognizing N-domain of midkine, Cellmid (ASX: CDY), 18 April 2017
US Patent 9,622,955, Method of treatment or prevention of hair loss or for the enhancement of hair growth, Cellmid (ASX: CDY), 18 April 2017
US Patent 9,616,121, Therapeutic combinations for treating Johne's disease, Center for Digestive Diseases, 11 April 2017
US Patent 9,616,072, Reduction of side effects from aromatase inhibitors used for treating breast cancer, Chavah Pty Ltd, 11 April 2017
US Patent 9,611,312, Preparation and/or formulation of proteins cross-linked with polysaccharides, Elastagen, 4 April 2017
US Patent 9,610,337, Prevention and treatment of mycobacterium infection, Centenary Institute of Cancer Medicine and Cell Biology, 4 April 2017
US Patent 9,605,079, Proteins that bind PI16 and uses thereof, Medvet Science, 28 March 2017
US Patent 9,598,467, Recombinant HCV E2 glycoprotein, Macfarlane Burnet Institute for Medical Research and Public Health, 21 Match 2017
US Patent 9,597,392, Use of high molecular weight mannan for inducing and/or enhancing an immune response, Ascend Biopharmaceuticals, 21 March 2017
US Patent 9,593,340, Expression system for modulating an immune response, Admedus (ASX: AHZ), 14 March 2017
US Patent 9,592,318, Topical analgesic composition, Animal Ethics Pty Ltd, 14 March 2017
US Patent 9,592,201, GI tract delivery systems, Commonwealth Scientific and Industrial Research Organisation, 14 March 2017
US Patent 9,587,104, Release media, University of Queensland, 7 March 2017
US Patent 9,586,914, Modulators of C3a receptors, University of Queensland, 7 March 2017
US Patent 9,585,969, Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 7 March 2017
US Patent 9,585,952, Cellular vaccine and method of inducing an immune response in a subject, University of Adelaide, 7 March 2017
US Patent 9,585,846, Anti-microbial composition, Wild Child, 7 March 2017
US Patent 9,580,714, Peptides for the specific binding of RNA targets, University of Western Australia, 28 February 2017
US Patent 9,580,496, Therapeutic canine immunoglobulins and methods of using same, Nexvet, 28 February 2017
US Patent 9,580,481, Immunogenic compositions and methods therefor, University of Queensland, 28 February 2017
US Patent 9,573,945, Anxiolytic compounds, Bionomics (ASX: BNO), 21 February 2017
US Patent 9,572,892, Polymer conjugate for delivery of a bioactive agent, PolyActiva, 21 February 2017
US Patent 9,572,852, Sugar extracts, The Product Makers (Australia) Pty Ltd, 21 February 2017
US Patent 9,572,817, Use of androgens for vascular regeneration and endothelial repair, Heart Research Institute, 21 February 2017
US Patent 9,567,586, EpCAM aptamer for detection of cancer stem cells, Deakin University, 14 February 2017
US Patent 9,566,318, Combination therapy, Biosceptre, 14 February 2017
US Patent 9,562,094, Companion animal treatments, Biosceptre, 7 February 2017
US Patent 9,562,086, Vitronectin:keratinocyte growth factor chimeras, Queensland University of Technology, 7 February 2017
US Patent 9,561,272, Compositions and methods for modulating immune responses, University of Queensland, 7 February 2017
US Patent 9,561,243, Composition comprising non-neutralised tocol phosphate and a vitamin A compound, Phosphagenics (ASX: POH), 7 February 2017
US Patent 9,561,201, Therapeutic compounds, Fibrotech Therapeutics, 7 February 2017
US Patent 9,555,015, Antimicrobial compositions and methods for their use, Dermcare-Vet, 31 January 2017
US Patent 9,554,995, Nanoemulsions, University of Queensland, 31 January 2017
US Patent 9,546,235, Peptide-hydrogel composite, University of Sydney, 17 January 2017
US Patent 9,540,478, Biodegradable polyurethane and polyurethane ureas, PolyNovo (ASX: PNV), 10 January 2017
US Patent 9,540,387, Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections, Biota, 10 January 2017
US Patent 9,539,316, Blood stage malaria vaccine, Griffth University and La Trobe University, 10 January 2017
US Patent 9,539,223, Methods for treating bacterial infections, Neoculi, 10 January 2017
US Patent 9,539,221, Method of treating airway diseases with .beta.-adrenergic inverse agonists, Invion (ASX: IVX), 10 January 2017
US Patent 9,533,138, Method of providing agents to the cochlea, University of New South Wales, 3 January 2017

New Zealand applications

Here are the 15 US patents relevant to New Zealand's Life Sciences sector that have been granted since the start of 2017, for an issuance rate of 0.3 applications per week:

US Patent 9,788,563, Encapsulation system for protection of probiotics during processing, PepsiCo (US) with Massey University

US Patent 9,783,574, Cardiovascular therapeutics, Otago Innovation, 10 October 2017
US Patent 9,770,609, Urea based skin treatment, Neat Feat Products, 26 September 2017
US Patent 9,764,037, Conjugate compounds, Victoria University of Wellington, 19 September 2017
US Patent 9,737,575, Use of lactic acid bacteria to treat or prevent eczema, University of Otago, 22 August 2017
US Patent 9,717,790, Sphingoglycolipid analogues, Victoria University of Wellington, 18 August 2017
US Patent 9,708,366, Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate, Neuren Pharmaceuticals, 18 July 2017
US Patent 9,650,418, Synthetic analogues of neural regeneration peptides, CuroNZ, 16 May 2017
US Patent 9,649,367, Contraceptive vaccines for mammals, Contravaccine, 16 May 2017
US Patent 9,649,299, Transdermal parasiticidal formulations, Donaghys, 16 May 2017
US Patent 9,629,859, Nitric oxide donors, University of Otago, 25 April 2017
US Patent 9,597,285, Extruded chewable formulation comprising bound water, Argenta, 21 March 2017
US Patent 9,586,985, Organic compounds as proantigens for natural killer T cells, Victoria University of Wellington, 7 March 2017
US Patent 9,580,464, Anti-inflammatory proteins and peptides and methods of preparation and use thereof, ManukaMed, 28 February 2017
US Patent 9,539,289, Immunostimulatory compositions and methods of manufacture, Apimed Medical Honey, 10 January 2017